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1. Introduction 
Fatty liver is a common ‘liver disease’ often free of symptoms or complaints but might even 
lead to severe stages.  It is characterized by lipid deposition in hepatocytes both, for 
alcoholic as well as and non-alcoholic fatty liver. An additional inflammatory reaction 
results in - alcoholic (ASH) or non-alcoholic (NASH) - steatohepatitis. Steatohepatitis is 
characterized by both, inflammatory infiltrates of mixed cells in the small liver lobules as 
well as liver cell injury in terms of ballooning. NASH resembles alcoholic liver disease, but 
occurs in people who consume little or no alcohol. Many people with NASH don’t feel sick 
and are not aware of their liver problem. Nevertheless, NASH can get severe and can result 
in cirrhosis with permanent tissue damage. 
It has long been known that the typical manifestations of alcoholic liver damage (including 
cirrhosis of the liver) can also be found in patients who consume no alcohol. For such 
persons the incorrect diagnosis of ‘alcohol-related liver disease’ on the basis of just 
histopathological findings can have grave social, legal, and insurance implications. 
The term ‘non-alcoholic steatohepatitis’ (NASH) was established by Ludwig et al. in 1980. 
The terminology was later expanded (Bacon et al., 1994). Patients were described who 
manifested the typical histomorphological pattern of alcoholic steatohepatitis (ASH), but 
without or with only moderate alcohol consumption (Ludwig et al., 1997).  
Diagnosis by means of biopsy is the gold standard for differentiation between reversible 
steatosis and progressive steatohepatitis. There are numerous publications on this topic with 
the aim of developing uniform standards for biopsy diagnosis or identifying reliable non-
invasive or only slightly invasive alternatives to biopsy, particularly driven by the 
increasing prominence of alcoholic and non-alcoholic steatohepatitis. 
The term non-alcoholic fatty liver (NAFL) is not restricted to adults but also used to describe 
the same condition in children and adolescents (Baumann, 2005). Accordingly, the term non-
alcoholic steatohepatitis (NASH) is used in the paediatric age group for the more aggressive 
form of hepatocellular degeneration accompanied by fibrosis (Rashid & Roberts, 2000; 
Roberts, 2002). People at increased risk of developing a fatty liver, as well possess an 
increased risk of developing chemotherapy-associated steatohepatitis (CASH).  
Diagnostic procedures in patients with suspected fatty liver disease should be standardized 
and generally accepted. The goal of this chapter is thus to delineate the current concepts of 
aetiology, diagnostic as well as differential diagnostic of patients with fatty liver disease 
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with regard to the pathohistological diagnosis and to provide expert assessment of the non-
invasive alternatives. 
The present book chapter is adapted from the German Leitlinie ’Histopathologische 
Diagnose der nichtalkoholischen und alkoholischen Fettlebererkrankung’ (Tannapfel et al. 
2009), under the auspieces of the ’Deutsche Gesellschaft für Pathologie’, and under 
participation of the ’Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen 
(DGVS) ’, the ’Deutsche Diabetes Gesellschaft (DDG), the Berufsverband Deutscher 
Pathologen, the ’Kompetenznetz Hepatitis (HepNet) ’, the ’Gesellschaft für Pädiatrische 
Gastroenterologie und Ernährung (GPGE) ’, the ’Österreichische Gesellschaft für Pathologie 
(ÖGP) ’, the ’Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) ’, 
the ’Schweizerische Gesellschaft für Pathologie (SGPath) ’. 
2. Definitions and diagnostic criteria 
2.1 Definitions 
An alcoholic (AFL) and a non-alcoholic fatty liver (NAFL) characteristically show variable 
amounts of lipid deposition - principally triglycerides - in hepatocytes. Involvement of more 
than 5% of hepatocytes is termed ‘fatty degeneration’. If more than 50% of these cells are 
affected a ‘fatty liver’ is present. A subsequent inflammatory reaction with ballooning of the 
hepatocytes results in steatohepatitis.  
NASH resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. 
The major feature in NASH is fat in the liver, along with inflammation and damage. NASH 
can be severe as ASH and may lead to fibrosis or cirrhosis, in which the liver is permanently 
damaged.  
Light-microscopically detectable deposition of lipid droplets in the cytoplasm of hepatocytes 
is termed steatosis. Microvesicular and macrovesicular steatosis can be distinguished; mixed 
forms occur (Burt et al., 1998). For the accumulation of fat in the liver four pathogenetic 
processes are responsible: 1. Increased uptake of free fatty acids via the portal vein (from 
food or body fat), 2. Increased synthesis of free fatty acids in the liver (from glucose or 
acetate), 3. Decreased β-oxidation of free fatty acids, 4. Decreased synthesis or secretion of 
very low density lipoproteins (VLDL) the pathway for elimination of lipids from the liver 
(Burt et al., 1998).  
In the past, alcohol was usually suspected as the cause of steatosis. However, steatosis 
frequently can be observed in adiposity, diabetes mellitus type II and hyperlipidaemia – 
components of the so-called “Metabolic Syndrome”. Moreover, other factors such as toxins, 
medications, congenital metabolic disorders (e.g. a-beta-lipoproteinaemia/hypo-
betalipoproteinaemia), hormonal imbalances (as observed in polycystic ovary syndrome) or 
other to date unknown causes may lead to steatosis  (Church et al., 2006; Dancygier, 2006; 
Farrell& Larter, 2006). The morphological spectrum of non-alcoholic fatty liver disease 
(NAFLD) stretches from simple steatosis over steatohepatitis to liver fibrosis and cirrhosis, 
and thus ultimately to hepatocellular carcinoma. While pure steatosis is in principle 
reversible, steatohepatitis represents the progressive lesion in this spectrum. 
NAFLD is thought to be the most frequent liver disease in the western industrial nations 
and thus the commonest cause of elevated transaminases. The diagnosis of NAFLD is made 
on basis of clinical (exclusion of significant alcohol consumption) combined with 
histopathological (demonstration of steatosis or steatohepatitis) findings. Significant alcohol 
consumption is defined as more than 20 g alcohol per day in women and as more than 40 
g/day in men (Brunt, 2001; Neuschwander-Tetri & Caldwell, 2003).  
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The prevalence of NAFL in the western industrial nations is assumed to be 20 - 30%, that of 
NASH 2 – 3% (Cortez-Pinto et al., 2006; Dancygier, 2006; Day, 2006). There is a direct 
relationship with body weight: In obesity (BMI >30) the prevalence of sonographically 
detectable steatosis is 76 - 89%, compared with 46 - 50% in alcoholics (Bellentani et al., 2004). 
NAFLD is increasingly being diagnosed in childhood, again predominantly in association 
with obesity, but occasionally with suprasellar tumours (Alfire & Treem, 2006). 
The natural course of NAFLD in the individual case cannot be predicted. Only a small 
proportion of those affected show progression of their liver disease. The assumption is that 
simple steatosis will progress to NASH in around 10 - 20% of patients, and that of these, less 
than 5% will develop cirrhosis (Day, 2006; Kacerovsky & Roden, 2007; Mendez-Sanchez et 
al., 2007). Nevertheless, NAFL and NASH are currently believed to be the most important 
cause of so-called cryptogenic cirrhosis of the liver (Farrell& Larter, 2006; Caldwell et al., 
1999). 
The pathogenesis of NASH remains unclear. In the so called “two-hit” hypothesis, 
accumulation of free fatty acids and triglycerides in the liver (simple steatosis) represent a 
first hit, rendering the organ more vulnerable to a second hit that leads to steatohepatitis 
and ultimately, in the event of persisting or recurring damage, to fibrosis and cirrhosis (Day 
& James, 1998; Day, 2002).  
Insulin resistance seems to play a central part (Chitturi et al., 2002). It can be observed in 
virtually all patients. As a consequence of elevated peripheral lipolysis and decreased 
glucose uptake by the musculature, uptake of free fatty acids from the bloodstream rises.  
This leads to an increase in hepatic triglyceride synthesis and simultaneous inhibition of 
triglyceride secretion in the form of VLDL as a result of decreased apoprotein synthesis. The 
increase in the hepatic pool of free fatty acids leads to a rise in mitochondrial and 
peroxisomal β-oxidation with formation of reactive oxygen species (ROS), and thus to 
oxidative stress and increased lipid peroxidation. Facilitated by the action of 
proinflammatory cytokines (via activation of NF-κB, release of TNFα), steatohepatitis 
develops. Via Kupffer cell activation, liver fibrosis or cirrhosis arises (Farrell & Larter, 2006; 
Neuschwander-Tetri & Caldwell, 2003; Cortez-Pinto et al., 2006; Kacerovsky & Roden, 2007; 
Mendez-Sanchez et al., 2007; Duvnjak et al., 2007; Edmison & McCullough, 2007; Medina et 
al., 2004). The possible direct or indirect (increased insulin resistance) role of the adipocyte 
hormones (leptin and adiponectin) in the pathogenesis of NASH remains largely unclear. 
Another factor still discussed is the influence of bacterial overgrowth in the small intestine 
with endogenous production of ethanol and possible direct cytokine activation (Dancygier, 
2006; Edmison & McCullough, 2007; Targher et al., 2006). 
2.2 Diagnostic criteria 
Clinically, most patients with NAFLD exhibit no liver symptoms.  The disease is often 
suspected merely on grounds of (mildly) raised transaminase levels and/or gamma-
glutamyltranspeptidase (GGT). An ASAT/ALAT ratio of  > 1 points to an alcoholic 
aetiology. Patients with NASH often suffer from illnesses that go hand in hand with insulin 
resistance. However, the presence of a metabolic syndrome does not exclude alcoholic 
hepatopathy (Dufour & Oneta, 2004). 
In clinical practice, there is so far no means of differentiating reliably between simple 
steatosis and steatohepatitis solely on the basis of non-invasive (e.g. laboratory chemical) 
diagnostic tests (American Gastroenterological Association [AGA], 2002; Bellentani et al., 
2004; Farrell & Larter, 2006). Histological demonstration of persistent liver cell damage is 
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believed to be the best current marker for evaluation of disease progression (Gramlich et al., 
2004). The question of whether transaminase levels correlate with the histological findings 
has still not been answered definitively (Sonsuz et al., 2000), particularly with respect to 
necroinflammatory activity and the degree of fibrosis. Determination of the hepatic 
apoptotic activity in serum (activated caspase 3, keratin 18-fragment analysis) possibly has 
clinical value as a non-invasive diagnostic criterion for NASH (Wieckowska et al., 2006). 
Furthermore, isolated reports of non-invasive scoring systems for fibrosis have been 
published, but their potential diagnostic and/or prognostic role in clinical practice remains 
unclear (Angulo et al., 2007; Farrell & Larter, 2006). 
The morphological sign of non-alcoholic steatosis is a predominantly macrovesicular 
accumulation of lipids usually beginning at a perivenular site in the centre of a lobe. The 
lower limit has been set at fatty degeneration of 5% of the surface of the liver parenchyma 
(Kleiner et al., 2005; Neuschwander-Tetri & Caldwell, 2003). However, this does not seem to 
be adequately justified (Brunt & Tiniakos, 2005; Cortez-Pinto et al., 2006). Mild steatosis 
affects < 33% of the parenchymal surface, moderate steatosis involves 33 - 66%, and severe 
steatosis covers > 66% (Brunt, 2001, 2002, 2005a, 2005b; Brunt et al., 2003, 2004; Brunt & 
Tiniakos, 2002, 2005; Burt et al., 1998). The steatosis (of variable degree) is accompanied by 
usually slight mixed-cell inflammatory infiltrates (neutrophilic, granulocytic and 
lymphocytic cells) in the hepatic lobes. A further morphological criterion is cell ballooning, 
i.e. liver cell damage in the form of swelling. This can usually been seen in the vicinity of fat-
laden hepatocytes and thus also typically in the centre of a lobe. Other typical, albeit not 
diagnostically decisive parameters are lipogranulomas and periportal glycogen containing 
nuclei. Mallory-Denk bodies (MDB), usually can be demonstrated in the swollen cells. The 
fibrosis also starts in the centre of the affected lobe, in perivenular and perisinusoidal 
locations. Sometimes pericellular fibrosis can be detected. As the disease progresses, portal 
fibrosis with formation of portoportal and portocentral bridging septa arises. No single one 
of these structures should be used as a so-called ‘minimal criterion’ without the 
simultaneous demonstration of ballooning (Brunt, 2001, 2002, 2005a, 2005b; Brunt et al., 
2003, 2004; Brunt & Tiniakos, 2002, 2005; Burt et al., 1998 Neuschwander-Tetri & Caldwell, 
2003). 
The Cleveland group suggested classification of NAFLD (on prognostic grounds) into the 
following types:  
Type 1, simple steatosis 
Type 2, steatosis and inflammation 
Type 3, steatosis and cell swelling (ballooning) 
Type 4, steatosis, cell swelling (ballooning), and MDB or fibrosis  
Progression to cirrhosis is found predominantly in types 3 and 4, both of which correspond 
to the typical histopathological picture of NASH (Brunt, 2001, 2002, 2005a; Brunt et al., 2003, 
2004; Brunt & Tiniakos, 2002, 2005; Neuschwander-Tetri & Caldwell, 2003 Falck-Ytter et al., 
2001; Matteoni et al., 1999). For morphological manifestations of paediatric NASH (see 5.3). 
3. Indication for biopsy 
While scientists have been searching for non invasive diagnostic procedures for confirming 
diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease, 
to date histological evaluation remains the sole method of distinguishing steatosis from 
advanced forms of NAFLD. 
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Thus, liver biopsy is the gold standard for confirmation of the diagnosis and for 
determination of the inflammatory activity and possible presence of fibrosis in fatty liver 
disease. In deciding whether biopsy is indicated, one should weigh the potential 
information gain and its consequences against the resources invested and the complication 
rate, i.e. consider the clinical context. No blanket recommendation for liver biopsy in either 
suspected or confirmed fatty liver disease can currently be given. 
The indication for biopsy in assumed fatty liver disease depends on the clinical context. 
Decisive is the likelihood that the biopsy findings will have consequences for the patient’s 
behaviour or for therapy. These possible consequences include: 
Confirmation of fatty liver disease, in particular steatohepatitis, and its treatability; 
exclusion of steatohepatitis as cause of unexplained elevation of transaminases; exclusion or 
confirmation of comorbidities; ascertainment of status quo9,35,41,44 
Deciding the appropriate treatment approach (e.g. bariatric surgery, suitability for 
transplantation; treatment of any comorbidity) 
Motivation for behavioural modification or ascertainment of its effect (e.g. weight reduction, 
physical activity) 
Participation in clinical studies or protocol biopsies 
Special indications (e.g. assessment of explanted livers) 
In this context liver biopsy must clarify the following points: 
Confirmation of possible or assumed fatty liver; clarification of steatohepatitis; confirmation 
or exclusion of liver disease other than fatty liver disease (typing) 
Extent of inflammatory activity (grading) 
Degree of fibrosis and any destruction of hepatic architecture (staging) 
Liver biopsy is the current “gold standard” for analysis of these issues and cannot be 
replaced by any non-invasive procedure (Adams & Talwalkar, 2006; Angulo & Lindor, 2002; 
Brunt et al., 2004; Joy et al., 2003; Neuschwander-Tetri, 2002; Wieckowska et al., 2007). It is 
advisable to discuss the implications of liver biopsy with the patient during the course of 
diagnostic clarification of possible or probable fatty liver disease. While a pronounced case 
of fatty liver can be diagnosed with some certainty from the findings of clinical examination 
and imaging procedures, particularly the extent of the fatty degeneration and the presence 
or absence of the many possible accompanying liver diseases cannot be determined with 
any certainty by non-invasive means. There are no serological tests for diagnosis or 
quantification of fatty degeneration of the liver parenchyma. Comparative investigations 
have shown that elevation of serum transaminase concentrations can point to impairment of 
the hepatic parenchyma, but an absence of serum transaminase elevation in fatty liver 
disease does not exclude inflammatory activity in liver tissue (Mofrad et al., 2003). While in 
principle fatty liver disease is thought to be swiftly reversible and unlikely to progress, 
steatohepatitis entails a significant risk of progression to severe fibrosis or cirrhosis, so that 
the determination of inflammatory activity has considerable prognostic relevance Matteoni 
et al., 1999; Teli et al., 1995; Harrison ez al., 2003; Adams & Talwalkar, 2006;  Wieckowska et 
al., 2007). 
Numerous non-invasive procedures for diagnosis of liver fibrosis have been and are being 
developed. Serological tests are based on algorithms, some of which are independent of 
fibrosis while others integrate parameters associated with hepatic fibrogenesis (Younossi et 
al. 2008). Currently these tests can support the diagnosis of advanced liver fibrosis, but 
alone, particularly in the presence of only slight to moderate changes, they can neither 
confirm nor exclude fibrosis with sufficient certainty; therefore, they are unsuitable for 
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staging. Elastography is a method for determining the stiffness of the liver, which correlates 
with extent of fibrosis, at least during follow up. Particularly the presence or absence of 
severe fibrosis/cirrhosis can be assessed with high accuracy (Castera et al., 2008). The 
advantages of this method are its repeatability, its low inter- and intra-observer variability 
and its lack of side effects; its disadvantages are inadequate detection of slight and moderate 
fibrosis, lack of grading ability, significant interference by other liver changes (fatty 
degeneration, inflammatory activity, cholestasis, congestion) and by extrahepatic factors 
(morbid obesity, ascites) (Friedrich-Rust et al., 2008). For these reasons the diagnostic 
potential of elastography in fatty liver disease has been evaluated in only a few studies to 
date, so the method has not yet been adequately validated. In particular its role in the 
monitoring of the course of fatty liver disease should be further investigated. None of the 
tests mentioned above is suitable for assessment of destruction of hepatic architecture. Other 
procedures, e.g. magnetic resonance elastography for measurement of fibrosis (Bonekamp et 
al., 2009), are currently inadequately validated or not validated at all, and therefore cannot 
be recommended. 
Although liver biopsy is superior to all other investigations with regard to number of 
relevant parameters assessed and predictive power, it cannot always be recommended as 
diagnostic method in possible or sufficiently confirmed fatty liver disease. Several factors 
affect the decision whether or not to perform biopsy: 
Because biopsy is an invasive technique, the information it can be expected to yield must be 
balanced against the resources invested and the – albeit low – complication rate. The rate of 
fatal complications of liver biopsy is generally reported as 0.01%. Major intervention- or 
hospitalisation-related complications such as intraperitoneal haemorrhage occur in about 
0.3% of cases, while more minor complications, e.g. transient pain, are observed in 20 - 30% 
of patients (Strassburg & Manns, 2006). 
The issue of clinical consequences: The current treatment options for fatty liver disease are 
limited. Biopsy sampling of liver tissue for examination may be particularly useful, 
however, before invasive treatment measures such as bariatric surgery or liver 
transplantation (Tannapfel & Reinacher-Schick, 2008). In the medium term novel treatments, 
including medicinal approaches can be expected, entailing reassessment of the value and 
necessity of liver biopsy. To what extent knowledge of the findings of liver biopsy 
influences the patient’s behaviour (weight reduction, physical activity) has to be considered 
on an individual basis. 
Donor livers with < 30% fatty degeneration can be transplanted with no danger of primary 
transplant failure (Nocito et al., 2006).  
4. Harvesting and processing of biopsy material / histomorphological 
evaluation / scoring system 
The structural diagnostic criteria for NAFLD may be unevenly distributed in the liver. Thus, 
histological diagnosis on the basis of biopsy samples may be associated with possibly 
considerable sampling error (Ratziu et al., 2005). This may affect both, the diagnostic 
differentiation between steatosis and steatohepatitis and estimation of the extent of fibrosis 
(staging).  
Harvesting and processing of the biopsy cylinder should observe the standard 
recommendations for liver biopsy. The cylinder should contain representative tissues, be 
about 25 mm long and or contain 15 portal fields (Rousselet et al., 2005). Fixation and 
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processing are routine (4% neutral buffered formalin, embedding in paraffin with the usual 
dehydration and preparation of routine stains such as haematoxylin and eosin, Berlin blue 
for demonstration of iron, PAS-diastase stain and reticulin and connective tissue staining). 
Sirius red staining is recommended for morphometric assessment. Immunohistological 
staining is not routinely required. An immunohistochemical reaction with antibodies to 
keratin 7 or 19 can be carried out to facilitate demonstration of gall duct lesions. Sensitive 
depiction of any MDB that may be present can be achieved with ubiquitin antibodies. With 
regard to ballooning of hepatocytes, which is included in the scoring system, demonstration 
of the intermediate filament cytoskeleton with antibodies against keratin 8 or 18 may be 
helpful, as this cytoskeletal system is reduced in cell ballooning (Lackner et al., 2008). The 
staging of fibrosis is shown in Table1. 
The following histological criteria should be considered when interpreting and diagnosing 
non-alcoholic steatohepatitis: micro- or macrovesicular fatty degeneration, fibrosis, lobular 
inflammation – typically comprising polymorphonuclear granulocytes, lymphocytes and 
activated Kupffer cells – lipogranulomas, hepatocyte ballooning, acidophilic bodies, ceroid-
containing macrophages and megamitochondria. Additional changes are MDB and 
glycogen-contaning nuclei. 
 
Stage Histological findings 
0 No fibrosis 
1a Zone 3, perisinusoidal fibrosis, special staining (i.e. EvG) required 
1b Zone 3, perisinusoidal fibrosis, can be detected with H&E 
1c Only periportal/portal fibrosis 
2 Zone 3, plus portal/periportal fibrosis 
3 As above, but with bridging fibrosis 
4 Cirrhosis 
Table 1. Degree of fibrosis (staging) 
Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a ‘Brunt 
Score’ (Brunt et al., 1999) (Table 2) or ‘NAS’ (NAFLD activity score; Table 3), providing the 
basis on which to decide whether or not steatohepatitis is present.  
 
Activity Steatosis Ballooning Inflammation 
Mild: grade 1 1 – 2 (up to 66%) Minimal 
Lobular: 1 – 2 
Portal: none to mild 
Moderate: grade 
2 
2 – 3 (> 33%, 
occasionally > 66%) 
Clear 
Lobular: 2 
Portal: mild to 
moderate 
Severe: grade 3 3 (≥ 66%) Marked 
Lobular: 3 
Portal: mild to 
moderate 
Table 2. NASH activity grading. Steatosis grade 1: ≤ 33%; grade 2: > 33%, < 66%; grade 3: ≥ 
66% 
The NAS (NAFLD activity score) is a refinement of the Brunt score, derived by separate 
semiquantification of each of the three components – steatosis, hepatocyte ballooning and 
lobular inflammation – and addition to form a total score. 
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NAS 
Steatosis (% fat 
deposition in 
hepatocytes) 
Ballooning 
hepatocytes 
Lobular 
inflammation 
0 < 5% (0) None (0) None (0) 
3 5 – 33% (1) Few (1) 
1– 2 foci per 200x 
field (1) 
6 34 – 66% (2) Many (2) 
2 – 4 foci per 200x 
field (2) 
8 > 66% (3) Many (2) 
> 4 foci per 200x field 
(3) 
Table 3. NAFLD activity score (grading): The numbers in parentheses give the NAS for each 
histological criterion 
Evaluation and semiquantitative analysis for grading (Brunt et al., 1999): 
Grade of fatty degeneration: 
< 5%   = grade 0 
5 – 33%   = grade 1 
34 – 66%   = grade 2 
More than 66%  = grade 3 
Grade of lobular inflammation: 
Absent       = grade 0 
Up to 2 foci per field of view (200× magnification)  = grade 1 
2 to 4 foci per field of view    = grade 2 
More than 4 foci per field of view    = grade 3 
Lipogranulomas are included in the category of inflammation 
Ballooning: 
Absent      = grade 0 
Few ballooned hepatocytes   = grade 1 
Many ballooned hepatocytes   = grade 2 
This scoring system is readily reproducible and can provide the basis for deciding whether 
steatohepatitis should be diagnosed or not: 
0 – 2  definitely no steatohepatitis 
3 – 4  questionable 
5 or more definite steatohepatitis 
The scoring can also be applied to paediatric cases (Brunt EM, 2007; Schwimmer et al., 2005). 
The staging according to grade of fibrosis (Table 2b, after Kleiner et al., 2005) should also be 
evaluated:  
Stage 1 is divided into 1a with slight central fibrosis and 1b with dense perisinusoidal 
fibrosis accompanied by central vein sclerosis and adjacent perisinusoidal fibrous extension. 
Stage 1c is used only for portal fibrosis, which may certainly occur at an early stage. Stage 2 
is portal and central fibrosis. In analogy with the staging of chronic hepatitis, stage 3 is 
bridging fibrosis and stage 4 corresponds to cirrhosis. 
The presence of MDB should also be recorded (Mendler et al., 2005). 
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The proposed scoring systems have not yet been generally accepted. Numerical scores alone 
should not replace histological diagnosis.  
In Figures 1 – 4 typical images of different histopathological conditions for both, grade of 
steatosis and grade of fibrosis are presented. 
 
 
Fig. 1. Non-alcoholic steatohepatitis: fat 10 %, score: 1 plus 1 plus 1 = 3, fibrosis grade 1B 
 
 
Fig. 2. Non-alcoholic steatohepatitis: fat 8%, score 1 plus 1 plus 1 = 3, fibrosis grade 1c 
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Fig. 3. Non-alcoholic steatohepatitis:  fat 30%, score 1 plus 1 plus 1 = 3, fibrosis grade 3 
 
 
 
Fig. 4. Non-alcoholic steatohepatitis with cirrhosis: fat 40%, score: 2 plus 2 plus 1 = 5,   
fibrosis grade 4 
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5. Diagnosis and differential diagnosis 
It is important to differentiate between ASH and NASH and also to differentiate both of 
them from viral hepatitides and chemotoxicity-related steatohepatitides. The 
histopathological peculiarities of fatty liver diseases in the paediatric age group must also be 
borne in mind. 
The criteria used for the morphological definition of steatohepatitis are fatty degeneration of 
liver cells (steatosis), predominant in zone 3, lobular and/or portal field-dominant 
inflammatory reaction (inflammation), direct liver cell damage in the form of ballooned 
hepatocytes, possibly Mallory-Denk bodies (MDB), fibrosis and possibly accumulation of 
iron. 
- Steatosis 
Fatty degeneration of liver cells is documented in virtually all existing studies on ASH and 
NASH4. 
Macrovesicular steatosis results from the discrepancy between synthesis of lipids and their 
export from the hepatocytes. 
Microvesicular steatosis, a possible precursor of macrovesicular steatosis, is thought to be a 
consequence of severe hepatocytic damage as a result of defective β-oxidation of fatty acids. 
The toxic effects of some medicinal drugs can also lead to microvesicular steatosis. 
In the course of ASH or NASH there may be complete loss of fat; thus, for example, 
cryptogenic cirrhosis with only slight fatty degeneration of liver cells is not infrequently 
ascribable to NASH (Caldwell et al., 1999; Oneta & Dufour, 2003). 
- Lobular and/or portal inflammation and hepatocyte ballooning 
ASH and NASH are characterised by a lobular inflammatory cell infiltrate with a variable 
number of leucocytes. Not infrequently the inflammatory cells are found to enclose 
ballooned hepatocytes. So-called lipogranulomas, i.e. inflammatory cells (including Kupffer 
cells and eosinophilic granulocytes) enclosing a fat-laden hepatocyte, may be seen but are 
not considered pathognomonic for NASH or ASH (Caldwell et al., 1999; Reid, 2001). 
The direct hepatocyte damage is shown by the aforementioned ballooning, which may 
progress to necrosis or apoptosis. Hepatocytes of zone 3 are affected most frequently (Brunt, 
2005; Brunt & Tiniakos, 2005; Burt et al., 1998; Neuschwander-Tetri & Caldwell , 2003). MDB 
do not contribute to differentiation between ASH and NASH. 
- Fibrosis 
The characteristic fibrosis pattern in ASH and NASH is pericellular fibrogenesis. Collagen is 
found in the Disse spaces. In both ASH and NASH, zone 3 is affected first, with periportal 
fibrosis not infrequently observed in the liver of patients with diabetes mellitus type 1 (NASH 
patients). It seems that portal field fibrosis tends to predominate in ASH. Taken alone, 
however, this pattern of fibrosis is not a criterion for differentiation between ASH and NASH. 
5.1 Differential diagnosis of alcoholic (ASH) and non-alcoholic steatohepatitis (NASH) 
In general, histological criteria alone do not permit confident differentiation between ASH 
and NASH (Oneta & Dufour, 2003). Nevertheless, some findings may be helpful in 
differential diagnosis (Brunt, 2002; Brunt, 2007), although to date there is no published 
evidence: 
- Fat 
Microvesicular steatosis and “foamy” degeneration of the liver seem to indicate incipient 
hepatic decompensation in patients with ASH and are less common in NASH. 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
24 
Patients with NASH usually exhibit more advanced fatty degeneration of liver cells than 
those with ASH. The affected hepatocytes, concentrated at periportal sites, more frequently 
display intranuclear vacuoles. 
In addition to the nuclear vacuoles, patients with diabetes mellitus show fibrosis usually 
starting in zone 1, where MDB may also be found. Patients with NAFL who display 
pronounced weight increase or a jejunoileal bypass tend to exhibit portal inflammation with 
only slight portal fibrosis. 
Only in decompensated ASH may any appreciable cholestasis occur, usually 
intracanalicular and sometimes with a secondary phenomenon such as pancreatitis or 
haemolysis as a contributory cause. 
-      Inflammation 
As a general rule, the inflammatory infiltrate in NASH is somewhat less pronounced than in 
ASH. MDB are more frequent and more distinctive in ASH than they are in NASH. So-called 
satellitosis, granulocytic demarcation of a hepatocyte with MDB, is more frequent in ASH 
than in NASH. 
-     Fibrosis 
Indicative, though not specific, for ASH are the so-called sclerosing hyaline necroses, 
usually in combination with obliterating vascular lesions. The latter are also considered to 
be responsible for the non-cirrhotic 00portal hypertension in patients with ASH. Sclerosing 
hyaline necroses are thought to represent a combination of liver cell necrosis and loss 
(predominantly in zone 3) and dense perivenular and perisinusoidal fibrosis to the point of 
venous obliteration (with or without MDB). 
 
Finding ASH NASH 
Steatosis + ++ 
Ballooning ++ ++ 
Lobular inflammation ++ +/++ 
Portal granulocytic inflammation ++ --/+ 
Mallory-Denk bodies (MDB +++ + 
Satellitosis +++ -- 
Acute cholestasis + -- 
Perisinusoidal fibrosis + + 
Sclerosing hyaline necrosis ++ -- 
Veno-occlusive disease (VOD) ++ -- 
Table 4. Criteria for differentiation of ASH and NASH 
Venous or perivenular fibrosis, phlebosclerosis and (less commonly) lymphocytic phlebitis 
occur more frequently in ASH than in NASH. Phlebosclerosis is a frequent sign of alcohol-
associated cirrhosis of the liver. 
Cholestasis is found in around a third of all livers with ASH, less often in patients with 
NASH. Ductular proliferates are encountered more frequently in ASH than in NASH. 
Criteria for differentiation of ASH and NASH see table 4. 
5.2 Differential diagnosis of ASH, NASH / hepatitis / drug-induced hepatitis 
The criteria for differentiation of NASH or ASH from hepatitis C virus infection are firstly 
the characteristic portal inflammatory infiltration pattern of HCV infection, and secondly 
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the lack of typical hepatocyte ballooning and the intra-acinar granulocytic inflammation 
(Sanyal et al., 2006). 
Differentiation among ASH / NASH, hepatitis C virus infection and liver damage by toxic 
effects of medications (‘drug-induced hepatitis’) is possible. In patients exhibiting signs of 
more than one of these diseases, discussion embracing the clinical parameters is necessary to 
identify the essential contributory factors. 
Chronic HCV infection can also lead to macrovesicular steatosis. In particular, patients 
infected with HCV genotype 3 usually show more advanced fatty degeneration. However, 
the hepatocyte ballooning and intralobular granulocytic inflammation typical of ASH and 
NASH are absent. 
Drug-induced hepatitis is characterised by portal and particularly intra-acinar inflammation 
that consists principally of neutrophilic and eosinophilic granulocytes. Cholestasis is found, 
and in severe cases liver cell necrosis. Steatosis does not necessarily occur in drug-induced 
hepatitis (exceptions include tamoxifen and amiodarone), but is often found in patients who 
evince certain risk factors (high BMI, diabetes mellitus). Selected drugs that may lead to 
steatosis are e.g Acetylsalicylic acid, Amiodarone,  Didanosine (stavudine), MDMA 
(amphetamines). 
5.3 Special form: paediatric fatty liver disease 
As applies for adults both NAFLD and NASH can occur without any apparent risk factor 
even in children. The sole clinical manifestation is usually a persistent slight (one- to 
twofold) elevation in transaminases. In about 80% of the affected children and adolescents 
the NAFL is discovered incidentally in overweight or obese individuals. The remainder 
display normal weight but the majority are diabetics. 
Paediatric NASH exhibits histological differences from adult NASH. The question of liver 
biopsy is controversial; nevertheless, there is consensus that, particularly in the event of 
repeated elevation of liver enzymes, chronic liver diseases such as hepatitis B and C, 
Wilson’s disease and autoimmune hepatitides should first be ruled out. Weight reduction 
should be attempted. In patients who lose a moderate amount of weight over a period of six 
months but do not achieve normalisation of liver function, liver biopsy should be performed 
for definitive confirmation of the diagnosis and assessment of the prognosis. If at any time 
during this period evidence emerges of another disease or a competing or concurrent liver 
ailment (demonstration of autoantibodies, caeruloplasmin decrease), diagnosis should not 
be postponed until after weight reduction but ascertained immediately, with liver biopsy if 
necessary. 
For assignment of the diagnosis of NAFLD in childhood or adolescence, fat has to make up 
at least 5 - 10% of the liver by weight. In analogy to the classification of fatty liver disease in 
adults, the steatosis is categorised as mild (less than a third of hepatocytes affected), 
moderate (up to two thirds of hepatocytes affected) or severe (more than two-thirds of 
hepatocytes affected) (Hubscher, 2004). Among adults with NAFLD, 1 - 3% go on to develop 
cirrhosis of the liver. If this is true for the paediatric age group, many children are at 
increased risk of early progressive liver fibrosis or cirrhosis.  
Differences between paediatric and adult NAFLD: 
To date there have been no studies on the prognosis of NAFLD. It also remains unclear what 
influence puberty and growth have on the time course of the disease. Adult NASH patients 
have a 25% risk of developing advanced liver fibrosis within 5 years and a 15% risk of 
cirrhosis in the same period (Neuschwander-Tetri & Caldwell, 2003). The significance of 
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ethnicity is hotly debated. Children of Hispanic and Asiatic origin are at greater risk. In 
contrast to the situation in adults with non-alcoholic liver disease, males are predominantly 
affected in the paediatric age group (DeLeve et al., 2002; Roberts, 2007). 
The first study on the histopathology of paediatric NAFLD and hepatitis found that they 
largely resemble the picture in adult disease, but display differing morphological aspects. 
With regard to inflammation and fibrosis, two subtypes can be distinguished (Schwimmer 
et al., 2005). In general the livers of children and adolescents with NASH reveal less lobular 
and more portal inflammation, and the fibrosis tends to be more portal rather than 
perisinusoidal (Rashid & Roberts, 2000; Roberts, 2007; Papandreou et al., 2007). This 
distinctive histological feature could explain the early progression of the NAFLD score in 
children and adolescents compared with adults. Biopsy samples exhibit more marked fatty 
degeneration than in adult NASH. The characteristic ballooning of hepatocytes in adults is 
also absent, as is the pronounced lobular inflammation with perisinusoidal fibrosis. Only in 
12% of cases is paediatric NAFLD histologically comparable to the adult disease 
(Schwimmer et al., 2005;  Schwimmer, 2007). The differential diagnoses include Wilson’s 
disease, other disorders of hepatic metabolism (including rare diseases) and chronic 
inflammatory bowel diseases, which may manifest as diarrhoea with weight loss. 
Differentiation from hepatitis is particularly important.  
5.4 Special form: chemotherapy-associated steatohepatitis (CASH) 
Persons at increased risk of developing fatty liver are in greater danger of developing 
chemotherapy-associated steatohepatitis (CASH). Close monitoring of liver function before 
hepatic resection is recommended in these patients. Possible causes of elevation of liver 
enzymes before initiation of chemotherapy include malignant involvement of the liver and 
other chronic hepatic diseases as well as fatty liver disease. Liver biopsy may be necessary 
for differential diagnosis. 
Severe liver changes have been observed following chemotherapy administered in the 
context of liver resection, particularly extirpation of colorectal metastases. These adverse 
effects of chemotherapy on the liver tissue around a tumour can lead to postoperative 
impairment of liver function. 
The described changes resemble the histological findings after conditioning chemotherapy 
and subsequent allogenic stem cell transplantation in the liver. The liver damage after 
chemotherapy depends decisively on the degree of previous liver impairment. Neoadjuvant 
chemotherapy may be followed not only by sinusoidal obstruction syndrome (SOS) (DeLeve 
et al., 2002), but also by slight steatosis, steatohepatitis or even combined steatohepatitis and 
SOS (Karoui et al., 2006) . In principal, any of the cell populations in the liver can be affected 
by drug-induced damage. Cholangiocytes are considered to be relatively inert. Hepatocytes, 
followed by vascular endothelia, are the primary cell systems in which damage may also be 
visible on light microscopy. The changes may extend as far as fibrosis, accompanied by 
vascular wall damage and parenchymal bleeding.  
- Fatty degeneration of liver cells 
Fatty degeneration after chemotherapy with 5-fluorouracil (5-FU) is generally considered to 
be reversible after discontinuation of the treatment. Particularly in the case of pre-existing 
fatty liver, however, the rate of complications after liver resection is higher. Chemotherapy-
induced fatty degeneration of liver cells can lead to functional impairment after liver 
resection. 
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- Steatohepatitis (fatty liver hepatitis) 
It is known that, for example, 5-FU, taxanes or platinum-containing chemotherapeutics exert 
oxidative stress not only on tumour cells but also on non-neoplastic parenchymal and 
stromal cells (Tannapfel et al., 2001). This prompted the proposal to adopt the term 
“chemotherapy-associated steatohepatitis” (CASH) (Gentilucci et al., 2006; Zivkovic et al., 
2007). 
The metabolic pathway of some drugs is known in detail. Thus the topoisomerase-I inhibitor 
irinotecan (CPT11) is thought to trigger CASH even in a previously intact liver. The damage 
is assumed to be predominantly hepatocytic because of the glucuronidation of hepatocytes. 
Sublethal liver damage may be manifested by hepatocyte ballooning, microvesicular 
steatosis and finally inflammation with subsequent fibrosis. Like ballooning, hepatocellular 
cholestasis is considered to be a sign of direct cell damage. In the treatment of colorectal 
carcinoma irinotecan is almost always used in combination with 5-FU, so the hepatotoxic 
effects may be additive. 
- Vascular endothelial damage 
The endothelial cells can also be damaged by oxidative stress. Histologically, the vessels are 
occluded by connective tissue (Aloia et al., 2006; Vauthey et al., 2006; Zivkovic et al., 2007), 
with coexisting inflammation, fibrosis and embolic occlusion of small and larger 
downstream vessels. Damage of these cells in the terminal hepatic venules and sublobular 
veins causes on the one hand activation of the coagulation cascade (thrombosis) and on the 
other, hyperfibrinolysis (bleeding). These disseminated intravasal coagulations in the liver 
result in inflammation and subsequent fibrosis to the point of vascular occlusion. 
Macroscopically, the affected liver is rich in blood, spongy and livid (“blue liver”); its 
elasticity is diminished. 
Here too the effects of various substances may be additive. 
Platinum-containing chemotherapeutics (particularly oxaliplatin) also possess high 
hepatotoxic potential (endothelial damage, sinusoidal lesions, SOS). Resected liver tissue 
from patients treated with a combination of 5-FU and oxaliplatin reveal, besides sinusoidal 
lesions with bleeding, vascular thrombosis and vascular fibrosis, signs of CASH, with 
hepatocytic necrosis, fatty degeneration of liver cells and cholestasis. These changes may be 
visible as early as 20 days after inception of therapy. 
The histological changes after administration of site-specific treatments, e.g. monoclonal 
antibodies against the EGF receptor or VEGF, have not yet been the subject of controlled 
studies. 
- Classification system for staging 
The precise relationship between fatty degeneration of liver cells and SOS has not yet been 
clearly defined. A further open question is the dose-effect relationship. Moreover, it remains 
unclear whether the histological changes are reversible. There seems to be no linear 
correlation between liver damage and elevated liver enzymes in peripheral blood. To date 
there is neither a clinical nor a histological classification or graduation system that would 
allow “staging” of the change, much less prediction of the outcome. Therefore, it can merely 
be recommended that liver function be closely monitored before liver resection in patients at 
risk of developing fatty liver (e.g. high BMI, metabolic syndrome, diabetes mellitus) (Aloia 
et al., 2006; Nakano et al., 2008). If the liver enzymes are elevated before initiation of 
chemotherapy and the cause is not tumour involvement, a full battery of laboratory tests 
may need to be accompanied by liver biopsy to establish the exact extent of fatty 
degeneration, ballooning or fibrosis. In particular, special attention should be paid to 
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histological processing of the tissue surrounding the metastasis in specimens resected from 
patients who have undergone chemotherapy. 
6. Genetic prevalence 
At the moment, the question of genetic prevalence of NAFLD and NASH is under 
investigation and is obviously higher than estimated previously (Williams et al., 2011). 
Recently several genetic factors such as patatin-like phospholipase 3 or apolipoprotein C3 
have been characterized in NAFLD (Valenti et al., 2010; Petersen et al., 2010). Even genome-
wide association studies (GWASs) of liver histology in patients with non alcoholic fatty liver 
disease have been performed to estimate genetic susceptibility to NASH (Chalasani et al., 
2010). However, these findings have to be validated.  
7. Conclusion 
Diagnostic procedures in patients with suspected fatty liver disease should be standardized 
and generally accepted. The publications on predisposition to ASH or NASH, however, 
cannot be uniformly interpreted because of ethnic or physiological differences among the 
populations analysed. It is therefore important to evaluate the situation objectively and 
work towards reasonable diagnostic procedures that serve the needs of these patients. 
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